Illumina: Charles Dadswell, Scott Davies
Illumina announced that Charles Dadswell will step down as general counsel and secretary. He will stay on in an advisory role to the CEO and board through March 31, 2025. Dadswell served as interim CEO in 2023 following the resignation of former CEO Francis deSouza.
Effective Oct. 3, Chief Corporate Counsel Scott Davies will serve as interim GC and secretary.
Beckman Coulter Life Sciences: Joe Fox
Danaher subsidiary Beckman Coulter Life Sciences has appointed Joe Fox as president, effective immediately. Fox previously served as president of fellow Danaher subsidiary Sciex and held multiple leadership positions at the firm before his role as president, including as senior VP of global sales and service. He also held both technical and commercial roles with life science instrument firms Bruker and Shimadzu.
Oxford Nanopore Technologies: Daniel Mahony, Guy Harmelin
Oxford Nanopore Technologies has appointed Daniel Mahony as a nonexecutive director. A senior partner in growth investments at Novo Holdings, Mahony will serve as an Oxford Nanopore board member as it continues to address commercial opportunities in the biopharmaceutical industry. Mahony also currently chairs the UK BioIndustry Association and is a nonexecutive director of the Wellcome Sanger Institute.
Guy Harmelin, a nonexecutive director since 2020, has stepped down from the company this week to focus on various other directorship responsibilities.
Quanterix: Ivana Magovčević-Liebisch
Quanterix has appointed Ivana Magovčević-Liebisch to its board of directors.
Magovčević-Liebisch is president and CEO of Vigil Neuroscience. Prior to that, she was executive VP and chief business officer at Ipsen. She was also senior VP and head of global business development for the specialty drug business at Teva Pharmaceuticals as well as executive VP and chief operating officer at Dyax.
Akoya Biosciences: Scott Mendel
Akoya Biosciences has appointed Scott Mendel as chairman of its board. Mendel succeeds Robert Shepler, the company's founding chairman, who will remain on Akoya's board. Mendel previously served as president, CEO, and a board member of GenMark Diagnostics, a publicly traded molecular diagnostics company that was acquired by Roche in May 2020.
Nuclera: Gordon McInroy, Tobias Ost, Charu Maini
Gordon McInroy has been promoted to chief operating officer of Cambridge, UK-based protein expression firm Nuclera, from his previous post of chief technical officer. He holds a Ph.D. in chemistry and a master's degree in natural science from the University of Cambridge.
In addition, Tobias Ost has become senior VP of product development, moving on from his previous role as VP of R&D. In the past, he held senior leadership roles at Solexa, Cambridge Epigenetix (now Biomodal), and DNAe, as well as field application roles at Illumina and Pacific Biosciences. Ost holds a Ph.D. in enzymology and bioinorganic chemistry and a B.Sc. in chemistry from the University of Edinburgh.
Charu Maini has been promoted from VP of people to senior VP of people. He previously held other HR positions at Microsoft, American Express, and PricewaterhouseCoopers.
Genomics PLC: David Thornton, Gil McVean
David Thornton has been appointed as president of Genomics PLC. He succeeds Gil McVean, who will join the UK firm's board as a nonexecutive director. Thorton comes to Genomics PLC from Iqvia, where he was a senior VP and a member of the global executive leadership group, leading the commercial engagement services division. Previously, he held leadership and advisory positions at healthcare-focused companies.
VolitionRx: Ethel Rubin
VolitionRx has appointed Ethel Rubin to its board of directors, effective Sept. 30. She has also been appointed to the firm's audit committee and compensation committee. Rubin is currently head of ventures at BioHealth Innovation, leading a team of strategy and finance consultants. She previously was CSO and operations officer at BioFortis, now Q2 Solutions, and was CSO at CSA Medical, now Steris Healthcare. She was also at Medtronic where she held several leadership positions.
Integrated Biosciences: Keith Loebner, Karl Sylvester, Uri Alon, Wendy Young
Keith Loebner has been appointed to the board of directors of Integrated Biosciences, while Karl Sylvester, Uri Alon, and Wendy Young have been appointed as advisers. Loebner is a managing director at Sutter Hill Ventures, and an investor in the company. Sylvester is a professor of surgery and pediatrics at Stanford University; Alon is a professor at the Weizmann Institute of Science; and Young is an adviser to Google Ventures and a previous senior VP of Genentech's small molecule drug discovery division.
Imperagen: Rob Wilson, Andrew Almond
Rob Wilson has been appointed as CEO of Manchester, UK-based enzyme engineering firm Imperagen, taking over from Andrew Almond, who is assuming the post of chief information officer. Previously, Wilson held leadership roles at Codexis and DNA Script.
SeqBiome: David Corr, Marcus Claesson, Paul Cotter
David Corr has been appointed as CEO of Irish microbiome analysis firm SeqBiome, succeeding founding CEO Marcus Claesson, who will become the firm's head of bioinformatics. Cofounder Paul Cotter will take on the post of head of microbiology.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.